Plain language summary of the phase 3 study on Leniolisib treatment for people with activated PI3K delta syndrome (APDS)

This Plain Language Summary of publication article (PLSP) from Future Rare Diseases discusses a clinical study on leniolisib, a drug developed to treat activated PI3K delta syndrome (APDS), a rare immune disorder. APDS causes symptoms like infections, enlarged immune-related organs, and reduced quality of life. The study aimed to evaluate the effectiveness of leniolisib in treating people with APDS.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome’ and was published in Blood.

Visit Ash Publications using the link to read the original article.

• APDS
• immune system
• leniolisib
• plain language summary
• rare disease